Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Program
After football on WRAL: Patchy fog to start the school year. Where your kids will be likely to see it at the bus stop.
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Neurocrine Bioscienc
(NQ:
NBIX
)
152.81
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Bioscienc
< Previous
1
2
3
4
5
6
7
8
Next >
TG Therapeutics Stock Clears Technical Benchmark, Hitting 90-Plus RS Rating
December 07, 2023
TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.
Via
Investor's Business Daily
Analyst Expectations for Neurocrine Biosciences's Future
December 07, 2023
Via
Benzinga
Regeneron Pharmaceuticals Stock Sees A Relative Strength Rating Rise
December 06, 2023
Regeneron Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating
Via
Investor's Business Daily
Investors seeking growth at a reasonable cost should explore NASDAQ:NBIX.
December 01, 2023
Investors seeking growth at a reasonable cost should explore NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Via
Chartmill
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
November 23, 2023
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.
Via
Chartmill
CRISPR Therapeutics Stock Earns 88 RS Rating On U.K. Regulator News
November 17, 2023
CRISPR Therapeutics sees its Relative Strength Rating enter the 80-plus level.
Via
Investor's Business Daily
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
November 07, 2023
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
November 02, 2023
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
Earnings Outlook For Neurocrine Biosciences
October 30, 2023
Via
Benzinga
Madrigal Pharmaceuticals Stock Clears Benchmark, Hits 80+ RS Rating
November 17, 2023
Madrigal Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86.
Via
Investor's Business Daily
Amphastar Pharmaceuticals Stock Earns Composite Rating Upgrade
November 10, 2023
Amphastar Pharmaceuticals stock saw its IBD SmartSelect Composite Rating rise to 98 Friday, up from 93 the day before.
Via
Investor's Business Daily
Why Is Neurocrine Biosciences Stock Trading Lower Today?
November 10, 2023
Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)
Via
Benzinga
3 Biotech Moonshots to Bet on the Future of Health
November 06, 2023
Thanks to their potential blockbuster drugs, these three biotech stocks may yield huge returns for patent investors willing to take the risk.
Via
InvestorPlace
Topics
Intellectual Property
Exposures
Intellectual Property
Rocket Pharmaceuticals Stock Sees Improved Price Strength
November 02, 2023
On Thursday, Rocket Pharmaceuticals stock got an upgrade to its Relative Strength (RS) Rating, from 68 to 78
Via
Investor's Business Daily
Raymond James Maintains Outperform Rating for Neurocrine Biosciences: Here's What You Need To Know
November 01, 2023
Via
Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
October 12, 2023
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) on the Verge of a Major Breakout as a Strong Growth Stock?
Via
Chartmill
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
October 11, 2023
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
What 22 Analyst Ratings Have To Say About Neurocrine Biosciences
October 06, 2023
Via
Benzinga
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
October 16, 2023
Don't overlook NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—a stock with solid growth prospects and a reasonable valuation.
Via
Chartmill
Why Is Neurocrine Biosciences Shares Trading Higher Today?
October 05, 2023
Neurocrine Biosciences Inc (NASDAQ: NBIX) released topline data from the Phase 3 CAHtalyst Pediatric Study of crinecerfont in children and adolescents with classic congenital adrenal hyperplasia (CAH)...
Via
Benzinga
Exploring the Growth Potential of NASDAQ:NBIX as It Nears a Breakout.
September 28, 2023
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
NASDAQ:NBIX: a strong growth stock preparing for the next leg up?.
September 27, 2023
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?.
Via
Chartmill
NASDAQ:NBIX qualifies as a high growth stock and is consolidating.
September 26, 2023
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Via
Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
September 22, 2023
Why NEUROCRINE BIOSCIENCES INC ( NASDAQ:NBIX ) Is a Promising High-Growth Stock in the Midst of Consolidation.
Via
Chartmill
Analyst Expectations for Neurocrine Biosciences's Future
September 13, 2023
Via
Benzinga
GoDaddy To Rally Around 44%? Here Are 10 Other Analyst Forecasts For Wednesday
September 13, 2023
Needham cut the price target for Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) from $60 to $53. Needham analyst Gil Blum maintained a Buy rating. Rocket Pharmaceuticals shares rose 24.3% to $19.00 in...
Via
Benzinga
What's Going On With Neurocrine Biosciences Stock Today?
September 12, 2023
Neurocrine Biosciences Inc (NASDAQ: NBIX) announced positive topline data from the Phase 3 CAHtalyst Adult Study evaluating crinecerfont in adults with classic congenital adrenal hyperplasia (CAH) due...
Via
Benzinga
Can Neurocrine Erase Its Recent Setbacks With This Jump To An Eight-Month High?
September 12, 2023
The company is working on a treatment for a disorder than can cause children to begin puberty early.
Via
Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
September 08, 2023
Via
Benzinga
FDA Greenlights Expanded Use Of Neurocrine Biosciences' Ingrezza: Analysts Weigh In Depression Warning
August 21, 2023
The FDA approved Neurocrine Biosciences Inc's (NASDAQ: NBIX) Ingrezza (valbenazine) capsules for the treatment of adults with chorea associated
Via
Benzinga
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.